| 1 | 1 | | I |
|---|
| 2 | 2 | | 119THCONGRESS |
|---|
| 3 | 3 | | 1 |
|---|
| 4 | 4 | | STSESSION H. R. 679 |
|---|
| 5 | 5 | | To nullify the modifications made by the Food and Drug Administration |
|---|
| 6 | 6 | | in January 2023 to the risk evaluation and mitigation strategy for |
|---|
| 7 | 7 | | the abortion pill mifepristone, and for other purposes. |
|---|
| 8 | 8 | | IN THE HOUSE OF REPRESENTATIVES |
|---|
| 9 | 9 | | JANUARY23, 2025 |
|---|
| 10 | 10 | | Mrs. H |
|---|
| 11 | 11 | | ARSHBARGER(for herself, Mr. HERNof Oklahoma, Mr. BOST, Mrs. |
|---|
| 12 | 12 | | M |
|---|
| 13 | 13 | | ILLERof Illinois, Mr. WEBERof Texas, Mr. BABIN, Mr. MOOLENAAR, |
|---|
| 14 | 14 | | Mr. W |
|---|
| 15 | 15 | | EBSTERof Florida, Mr. BAIRD, Mr. HIGGINSof Louisiana, Mr. |
|---|
| 16 | 16 | | F |
|---|
| 17 | 17 | | EENSTRA, Mr. YAKYM, Mr. BIGGSof Arizona, Mr. PALMER, and Mr. |
|---|
| 18 | 18 | | G |
|---|
| 19 | 19 | | UEST) introduced the following bill; which was referred to the Com- |
|---|
| 20 | 20 | | mittee on Energy and Commerce |
|---|
| 21 | 21 | | A BILL |
|---|
| 22 | 22 | | To nullify the modifications made by the Food and Drug |
|---|
| 23 | 23 | | Administration in January 2023 to the risk evaluation |
|---|
| 24 | 24 | | and mitigation strategy for the abortion pill mifepristone, |
|---|
| 25 | 25 | | and for other purposes. |
|---|
| 26 | 26 | | Be it enacted by the Senate and House of Representa-1 |
|---|
| 27 | 27 | | tives of the United States of America in Congress assembled, 2 |
|---|
| 28 | 28 | | SECTION 1. NULLIFICATION OF MODIFICATIONS TO REMS 3 |
|---|
| 29 | 29 | | FOR MIFEPRISTONE. 4 |
|---|
| 30 | 30 | | (a) N |
|---|
| 31 | 31 | | ULLIFICATION.—The modifications made by the 5 |
|---|
| 32 | 32 | | Food and Drug Administration in January 2023 to the 6 |
|---|
| 33 | 33 | | VerDate Sep 11 2014 23:09 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H679.IH H679 |
|---|
| 34 | 34 | | kjohnson on DSK7ZCZBW3PROD with $$_JOB 2 |
|---|
| 35 | 35 | | •HR 679 IH |
|---|
| 36 | 36 | | risk evaluation and mitigation strategy under section 505– 1 |
|---|
| 37 | 37 | | 1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 2 |
|---|
| 38 | 38 | | 355–1) for mifepristone are hereby nullified. 3 |
|---|
| 39 | 39 | | (b) N |
|---|
| 40 | 40 | | OSUBSTANTIALLYSIMILARPROVISIONS.—The 4 |
|---|
| 41 | 41 | | Secretary of Health and Human Services (or any head of 5 |
|---|
| 42 | 42 | | any office, department, or agency of the Department of 6 |
|---|
| 43 | 43 | | Health and Human Services) shall not establish, imple-7 |
|---|
| 44 | 44 | | ment, or enforce any provision of a risk evaluation and 8 |
|---|
| 45 | 45 | | mitigation strategy under section 505–1 of the Federal 9 |
|---|
| 46 | 46 | | Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for 10 |
|---|
| 47 | 47 | | mifepristone that is substantially similar to any of the 11 |
|---|
| 48 | 48 | | modifications nullified by subsection (a). 12 |
|---|
| 49 | 49 | | Æ |
|---|
| 50 | 50 | | VerDate Sep 11 2014 23:09 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6301 E:\BILLS\H679.IH H679 |
|---|
| 51 | 51 | | kjohnson on DSK7ZCZBW3PROD with $$_JOB |
|---|